U.S., Aug. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07784985) titled 'A Phase 0/1 Study of NST-628 in Recurrent Grade 4 Glioma' on Aug. 19.
Brief Summary: This is an open-label, single arm, non-randomized, Phase 0 and expansion Phase 1 study of NST-628 in adult patients with recurrent Grade 4 glioma with high phosphorylated extracellular signal-regulated kinase (pERK) expression who are scheduled for surgical resection. This study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability, and anti-tumor activity of NST-628.
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
Glioma, Recurrent High Grade
Grade 4 Malignant Glioma
Intervention:
DRUG: NST...